BioCryst Pharmaceuticals is expected to report Q2 2026 revenue of $183.28 million and an EPS of $0.14, with its current stock price of $8.98 trading significantly below the $21.00 average analyst price target.
Investors are primarily focused on ORLADEYO net revenue as the company works to achieve its $1 billion peak sales goal. The quarter is seen as a pivotal point for commercial momentum, following a strategic shift to close its Birmingham discovery center and focus on external R&D collaborations. Market watchers are specifically looking for verification of the full-year 2026 ORLADEYO revenue guidance range of $625 million to $645 million and progress toward sustained GAAP profitability.